Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 16 clinical-stage investigational medicines (wholly owned and partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MMP7, GSK-4532990, Fazirsiran, GSK5637608, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, ARO-DUX4, ARO-DM1 and ARO-ATXN2.
企業コードARWR
会社名Arrowhead Pharmaceuticals Inc
上場日Dec 14, 1993
設立日2001
最高経営責任者「CEO」Dr. Christopher Richard (Chris) Anzalone, Ph.D.
従業員数609
証券種類Ordinary Share
決算期末Dec 14
本社所在地177 E Colorado Blvd
都市PASADENA
証券取引所NASDAQ Global Select Consolidated
国United States of America
郵便番号91105
電話番号16266964702
ウェブサイトhttps://arrowheadpharma.com/
企業コードARWR
上場日Dec 14, 1993
設立日2001
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし